Actively Recruiting

Age: 21Years - 98Years
All Genders
Healthy Volunteers
NCT03403699

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

Led by University of Alabama at Birmingham · Updated on 2026-01-22

20

Participants Needed

1

Research Sites

520 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects with diabetes and age matched controls. The human iPSC cells will be used to generate mesoderm cells for injection into the vitreous cavity of diabetic rodents and primate eyes. The ability of mesoderm cells to generate endothelial cells and pericytes in areas of degenerated capillaries will be examined. The human iPSCs will also be used to generate hematopoietic CD34+CD45+ cells. The combination of CD34+CD45+ cells derived from iPSCs and iPSC derived mesoderm will be examined in combination for their potentially beneficial effect to enhance the vessel formation.

CONDITIONS

Official Title

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

Who Can Participate

Age: 21Years - 98Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Any man or woman between the ages of 21 to 98 years
  • Must have a diagnosis of diabetes or be a healthy age-matched control
  • Willing and able to cooperate with eye exam and skin punch biopsy procedures
Not Eligible

You will not qualify if you...

  • Evidence of ongoing acute or chronic infection such as HIV, Hepatitis B or C, or tuberculosis
  • Ongoing malignancy
  • History of cerebral vascular accident or cerebral vascular procedure
  • Current pregnancy
  • History of organ transplantation
  • Presence of a graft
  • Patients with anemia
  • Presence of age-related macular degeneration (AMD), glaucoma, uveitis, known hereditary degenerations, or other significant ocular complications besides diabetic retinopathy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294

Actively Recruiting

Loading map...

Research Team

J

Jennifer Moorer

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here